A detailed history of Ellevest, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Ellevest, Inc. holds 1,874 shares of ALNY stock, worth $462,503. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,874
Holding current value
$462,503
% of portfolio
0.03%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$233.81 - $287.01 $438,159 - $537,856
1,874 New
1,874 $515,000
Q4 2023

Feb 06, 2024

SELL
$151.41 - $196.57 $10,295 - $13,366
-68 Reduced 4.8%
1,348 $258,000
Q3 2023

Nov 09, 2023

BUY
$170.77 - $211.65 $9,563 - $11,852
56 Added 4.12%
1,416 $250,000
Q2 2023

Aug 09, 2023

BUY
$185.01 - $212.05 $90,839 - $104,116
491 Added 56.5%
1,360 $258,000
Q1 2023

May 04, 2023

SELL
$182.66 - $235.53 $42,011 - $54,171
-230 Reduced 20.93%
869 $174,000
Q4 2022

Feb 03, 2023

BUY
$185.53 - $241.31 $2,040 - $2,654
11 Added 1.01%
1,099 $261,000
Q3 2022

Nov 02, 2022

BUY
$138.54 - $232.0 $13,576 - $22,736
98 Added 9.9%
1,088 $218,000
Q2 2022

Jul 18, 2022

BUY
$120.42 - $169.29 $23,843 - $33,519
198 Added 25.0%
990 $144,000
Q1 2022

Apr 19, 2022

SELL
$127.18 - $173.91 $19,458 - $26,608
-153 Reduced 16.19%
792 $129,000
Q4 2021

Jan 24, 2022

SELL
$159.56 - $209.29 $20,104 - $26,370
-126 Reduced 11.76%
945 $160,000
Q3 2021

Oct 19, 2021

BUY
$169.75 - $207.73 $10,524 - $12,879
62 Added 6.14%
1,071 $202,000
Q2 2021

Jul 13, 2021

BUY
$128.63 - $176.89 $12,091 - $16,627
94 Added 10.27%
1,009 $171,000
Q1 2021

May 03, 2021

BUY
$126.83 - $175.69 $27,902 - $38,651
220 Added 31.65%
915 $129,000
Q4 2020

Feb 04, 2021

BUY
$122.97 - $147.0 $16,600 - $19,845
135 Added 24.11%
695 $90,000
Q3 2020

Oct 26, 2020

BUY
$121.19 - $165.49 $67,139 - $91,681
554 Added 9233.33%
560 $82,000
Q2 2020

Jul 06, 2020

BUY
$104.21 - $156.44 $625 - $938
6 New
6 $1,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.4B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Ellevest, Inc. Portfolio

Follow Ellevest, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ellevest, Inc. with notifications on news.